- Home
- EIC vs PROK Comparison
EIC vs PROK Comparison
Compare EIC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- PROK
- Stock Information
- Founded
- EIC N/A
- PROK 2015
- Country
- EIC United States
- PROK United States
- Employees
- EIC N/A
- PROK N/A
- Industry
- EIC Finance/Investors Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EIC Finance
- PROK Health Care
- Exchange
- EIC Nasdaq
- PROK Nasdaq
- Market Cap
- EIC 348.9M
- PROK 334.8M
- IPO Year
- EIC 2019
- PROK N/A
- Fundamental
- Price
- EIC $13.31
- PROK $2.45
- Analyst Decision
- EIC
- PROK Buy
- Analyst Count
- EIC 0
- PROK 5
- Target Price
- EIC N/A
- PROK $6.25
- AVG Volume (30 Days)
- EIC 165.1K
- PROK 2.4M
- Earning Date
- EIC 11-13-2025
- PROK 11-11-2025
- Dividend Yield
- EIC 11.74%
- PROK N/A
- EPS Growth
- EIC N/A
- PROK N/A
- EPS
- EIC 0.70
- PROK N/A
- Revenue
- EIC $55,581,156.00
- PROK $527,000.00
- Revenue This Year
- EIC $37.84
- PROK $265.05
- Revenue Next Year
- EIC $23.33
- PROK N/A
- P/E Ratio
- EIC $19.09
- PROK N/A
- Revenue Growth
- EIC 56.39
- PROK N/A
- 52 Week Low
- EIC $12.10
- PROK $0.46
- 52 Week High
- EIC $16.71
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- EIC 47.16
- PROK 50.33
- Support Level
- EIC $13.05
- PROK $2.12
- Resistance Level
- EIC $13.45
- PROK $3.05
- Average True Range (ATR)
- EIC 0.18
- PROK 0.23
- MACD
- EIC -0.06
- PROK 0.03
- Stochastic Oscillator
- EIC 29.69
- PROK 35.48
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.